KPWS
ALXN

Kestra Private Wealth Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Kestra Private Wealth Services’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,661
Closed -$305K – 988
2021
Q2 		$305K Buy
1,661
+12
+0.7% +$2.06K 0.02% 670
2021
Q1 		$252K Sell
1,649
-101
-6% -$15.6K 0.02% 664
2020
Q4 		$273K Sell
1,750
-149
-8% -$19.1K 0.02% 583
2020
Q3 		$217K Buy
+1,899
New +$205K 0.02% 581

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Kestra Private Wealth Services's ALXN Position: Q3 2021 in Review

Kestra Private Wealth Services sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,661 shares — an estimated $305K sold.

Kestra Private Wealth Services first reported a position in ALXN in Q3 2020 and held it in 4 quarters. The position peaked at $305K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Kestra Private Wealth Services reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Kestra Private Wealth Services sold 1,661 Alexion Pharmaceuticals shares in Q3 2021, an estimated $305K.
  • Kestra Private Wealth Services first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Kestra Private Wealth Services's Alexion Pharmaceuticals position peaked at $305K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Kestra Private Wealth Services's 13F filing for Q3 2021, filed 21 Oct 2021.